Translational readthrough, observed primarily in less complex organisms from viruses to Drosophila, expands the proteome by translating select transcripts beyond the canonical stop codon. Here, we show that vascular endothelial growth factor A (VEGFA) mRNA in mammalian endothelial cells undergoes programmed translational readthrough (PTR) generating VEGF-Ax, an isoform containing a unique 22-amino-acid C terminus extension. A cis-acting element in the VEGFA 3 0 UTR serves a dual function, not only encoding the appended peptide but also directing the PTR by decoding the UGA stop codon as serine. Heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 binds this element and promotes readthrough. Remarkably, VEGF-Ax exhibits antiangiogenic activity in contrast to the proangiogenic activity of VEGF-A. Pathophysiological significance of VEGF-Ax is indicated by robust expression in multiple human tissues but depletion in colon adenocarcinoma. Furthermore, genome-wide analysis revealed AGO1 and MTCH2 as authentic readthrough targets. Overall, our studies reveal a novel protein-regulated PTR event in a vertebrate system.
INTRODUCTION
Vascular endothelial growth factor A (VEGF-A) induces migration and proliferation in vascular endothelial cells (ECs) and is essential for both physiological (e.g., embryogenesis) and pathological (e.g., tumorigenesis, retinopathy, and arthritis) angiogenesis (Ferrara, 2009; Hicklin and Ellis, 2005; Nagy et al., 2007) . ECs not only respond to VEGF-A but also express and secrete it, and EC-derived VEGF-A exhibits an intracellular activity essential for vascular homeostasis (Lee et al., 2007) . VEGF-A also increases vascular permeability (Senger et al., 1983) and is required for maintenance of the differentiated phenotype in ECs (Kamba et al., 2006) . Deletion of the VEGFA gene, even at a single allele, or a 2-fold increase of VEGF-A is embryonic lethal, demonstrating a precise VEGF-A dosage requirement during development (Carmeliet et al., 1996; Ferrara et al., 1996; Miquerol et al., 2000) . VEGF-A functions primarily through two tyrosine kinase receptors, VEGFR1 (or flt-1) and VEGFR2 (or KDR or flk-1), and neuropilin 1 serves as an important coreceptor (Soker et al., 1998) . Because VEGF-A is critical for the pathogenesis of vascularized solid tumors, agents that selectively target the protein, receptor, or signaling pathway have received substantial attention. As an example, bevacizumab, a monoclonal antibody that targets human VEGF-A, is an FDA-approved drug successfully used to treat metastatic colorectal cancer (Hurwitz et al., 2004) .
The VEGFA gene on human chromosome 6 comprises eight exons. Alternative splicing events at the sixth and seventh exons, which encode heparin-binding motifs, generate multiple isoforms, all of which exhibit proangiogenic activity. Interestingly, an alternative splicing event within exon 8 has been reported to generate an antiangiogenic isoform, termed VEGF-Ab (Bates et al., 2002; Harper and Bates, 2008) . The splicing event in VEGFAb mRNA replaces an exon encoding CDKPRR at the C terminus of canonical proangiogenic isoforms with SLTRKD (RLTRKD in B. taurus). VEGF-A expression is regulated by multiple posttranscriptional mechanisms, primarily involving the unusually long 3 0 UTR. Heterogeneous nuclear ribonucleoprotein (hnRNP) L binds a CA-rich element, promoting VEGFA mRNA stability under hypoxia (Shih and Claffey, 1999) . VEGF-A expression is also subject to exquisite translational control mechanisms. In one well-studied example, interferon-g stimulation of myeloid cells induces binding of the heterotetrameric GAIT (interferon-g-activated inhibitor of translation) complex to a cognate element in the VEGFA 3 0 UTR and inhibits its translation (Mazumder et al., 2003; Sampath et al., 2004) . A protein-directed RNA switch integrates disparate signals induced by hypoxia and interferon-g to further regulate VEGFA translation expression in myeloid cells (Ray et al., 2009 ). Interestingly, a mechanism that prevents complete translational silencing of VEGFA mRNA has been reported that forces a ''trickle'' of synthesis, underscoring the requirement for precise regulation of VEGF-A dosage in physiological conditions (Yao et al., 2012) . In addition, VEGFA mRNA is subject to 5 0 UTR-mediated regulation in which an internal ribosomal entry site drives alternative translation-initiation from an in-frame CUG codon (Huez et al., 2001) .
Translation of mRNAs normally terminates at an in-frame stop codon. However, in a few circumstances, translation can continue beyond the stop codon to a downstream stop codon, generating a C-terminal polypeptide extension. Such translational readthrough events are best understood in viruses (Li and Rice, 1989; Pelham, 1978) , but translational readthrough has also been observed in bacteria (Jalajakumari et al., 1989) , yeast (Namy et al., 2003) , and Drosophila (Dunn et al., 2013; Robinson and Cooley, 1997; Steneberg and Samakovlis, 2001) . In a few systems translational readthrough is ''programmed'' by cis-acting RNA elements downstream of the first stop codon, clearly distinguishing the process from readthrough resulting from errors of translation (Firth et al., 2011) . Limited evidence for readthrough of vertebrate mRNAs has been shown, namely, rabbit b-globin in rabbits and rat myelin protein zero; however, the functional significance of the readthrough products and the cis-acting RNA signals or other regulatory mechanisms have not been determined (Chittum et al., 1998; Yamaguchi et al., 2012) . Moreover, to our knowledge, trans-acting protein factors that bind RNA elements or otherwise regulate translational readthrough have not been observed.
Here, we demonstrate that VEGFA mRNA undergoes robust programmed translational readthrough (PTR) in mammalian ECs. The PTR event generates a VEGF-A isoform, termed VEGF-Ax (for ''extended''), with a 22-amino-acid C terminus extension. Remarkably, VEGF-Ax exhibits a function opposite to that of VEGF-A, namely, antiangiogenic activity. Readthrough is ''programmed'' by a 63 nt RNA segment following the canonical stop codon that serves a dual function, encoding the peptide extension of VEGF-A and also acting as a cis-acting regulatory element. hnRNP A2/B1 binds this element and promotes readthrough. The presence of VEGF-Ax in blood and its selective expression in multiple tissues, as well as differential expression in a solid tumor, indicate its pathophysiological significance. Recombinant VEGF-Ax reduced tumor progression and associated angiogenesis in a human xenograft tumor implanted in nude mice, demonstrating its antiangiogenic property in vivo. We have expanded the generality of our findings by a genomewide analysis that reveals additional validated readthrough targets, namely, AGO1 and MTCH2 mRNAs. Overall, our results not only demonstrate a novel PTR event in a vertebrate transcript but also identify a new antiangiogenic isoform of VEGF-A with a potential role as a suppressor of pathological angiogenesis.
RESULTS

Endothelial Cells Express and Secrete an Antiangiogenic Isoform of VEGF-A
Despite recent studies of the autocrine function of EC-derived VEGF-A in blood vessel angiogenesis and homeostasis (da Silva et al., 2010; Lee et al., 2007) , its paracrine function has not received much attention. We hypothesized that secreted, EC-derived VEGF-A might be an important contributor to EC migration and proliferation, which are essential for endothelial wound-healing responses and angiogenesis (Ausprunk and Folkman, 1977; Schwartz et al., 1978) . Unexpectedly, a VEGF-A-neutralizing antibody enhanced migration of bovine aortic ECs as indicated by the number of migrating cells in a razorwound assay, as well as by root-mean-square displacement and mean cell speed ( Figure 1A) . Likewise, the antibody increased EC proliferation determined fluorimetrically as total cell DNA ( Figure 1B) . Consistent with these observations, addition of EC-conditioned medium decreased EC migration (Figure 1C) . These surprising results indicate that EC-derived VEGF-A inhibits their own migration and proliferation, characteristic features of antiangiogenic VEGF-A isoforms. To test for the possible expression of VEGF-Ab isoforms, we sequenced 74 VEGFA cDNA clones from bovine aortic ECs (and six from mouse aortic ECs) but did not find VEGF-Ab-specific mRNA or any alternatively spliced VEGFA mRNA that can generate antiangiogenic isoforms. Instead, we identified only mRNAs corresponding to proangiogenic VEGF-A 164 and VEGF-A 120 (Figures S1A-S1C available online). Similarly, VEGF-Ab-specific mRNA was not detected by RT-PCR using primers designed to differentiate between VEGF-Ab and VEGF-A isoforms ( Figure S1D ).
VEGF-Ax Is a Novel Isoform Generated by Translational
Readthrough of VEGFA mRNA The paradoxical presence of antiangiogenic VEGF-A in the absence of VEGF-Ab-specific mRNA suggested the possibility of a novel antiangiogenic VEGF-A isoform generated from mRNA encoding the proangiogenic isoform. A critical clue was offered by the sequence of the VEGFA mRNA 3 0 UTR. In the human VEGFA 3 0 UTR, we observed an evolutionarily conserved UGA stop codon 63 nt downstream and in frame to the canonical stop codon ( Figure 1D ). Importantly, a 4 nt insertion in rodent 3 0 UTRs is offset by a 1 nt deletion, thereby preserving the in-frame nature of the stop codons. Moreover, a mutation in the downstream rodent stop codon generates the alternate UAA stop codon, providing additional evolutionary support for the significance of the in-frame stop codon. The amino acid sequence potentially encoded by the region between the stop codons is likewise conserved in mammals, but the sequence beyond the downstream stop codon exhibits weak conservation (Figures S1E and S1F). Based on these observations, we hypothesized that VEGFA mRNA translation might extend beyond its canonical stop codon, terminating at the downstream, in-frame stop codon. This translational readthrough event in human or bovine cells would generate a VEGF-A isoform containing a 22-aminoacid C terminus extension (including an amino acid replacement of the stop codon) ending with S/RLTRKD, the same six-aminoacid terminus reported to confer antiangiogenic activity in human VEGF-Ab ( Figure 1E ).
To test this hypothesis, we generated an antibody against the unique peptide, AGLEEGASLRVSGTR, generated by the proposed translational readthrough event and not present in VEGFAb or any other protein (or in silico-translated mRNA). A 20 kDa protein corresponding to the predicted size of the readthrough product, designated VEGF-Ax (for extended), was identified in lysates from bovine ECs (Figure 2A ). Expression was inhibited by transfection with three different VEGFA-specific small interfering RNAs (siRNAs), consistent with a VEGF-A isoform. Protein immunoprecipitated with anti-VEGF-Ax antibody was recognized by an anti-VEGF-A antibody that targets the N terminus, further verifying VEGF-Ax as a VEGF-A isoform ( Figure 2B ). To validate antibody specificity, human embryonic kidney 293 (HEK293) cells were transfected with myc-tagged VEGFA cDNA up to the downstream stop codon in which the canonical stop codon was replaced by Ala-encoding GCA to ensure efficient generation of the modified, extended isoform, denoted VEGF-Ax Ala .
Anti-VEGF-Ax antibody recognized VEGF-Ax Ala , but not VEGF-A, whereas anti-VEGF-A antibody recognized both isoforms ( Figure S2A ). As expected, anti-VEGF-Ax antibody did not recognize recombinant VEGF-Ab; however, anti-VEGF-Ab antibody did recognize VEGF-Ax Ala ( Figure S2B ). Finally, preadsorption of anti-VEGF-Ax antibody with AGLEEGASLRVSGTR peptide prevented recognition of the 20 kDa VEGFAx band, further validating antibody specificity ( Figure S2C ). VEGF-Ax expression also was observed in murine aortic and human umbilical vein ECs ( Figure 2C ) and in multiple other cell types including macrophages, hepatocytes, keratinocytes, and tumor-derived cell lines (Figure S2D) . To distinguish between VEGFAx and VEGF-A by protein molecular weight, EC lysates were deglycosylated, subjected to 16% Tricine gel electrophoresis, and immunoblotted with anti-VEGF-A and anti-VEGF-Ax antibodies. VEGF-Ax constitutes about 10% of all VEGF-A isoforms in EC lysates; however, VEGF-Ax is the predominant isoform in conditioned medium, constituting about 85% of the total ( Figure 2D ). Translational readthrough in VEGFA mRNA was further established by mass spectrometric analysis of the product generated by overexpressing in HEK293 cells VEGFA cDNA containing the canonical stop codon and the Ax-specific sequence upstream of a myc-His tag to facilitate purification. In addition to detection of VEGF-A-specific peptides, selected reaction monitoring revealed a spectrum consistent with RSAGLEEGASLR (S, Ser in place of stop codon) specific for the readthrough region; the profile was confirmed by the spectrum obtained from synthetic RSAGLEEGASLR peptide ( Figures 2E-2G ). Spectra consistent with Ser in place of the stop codon were observed in three out of three independent experiments. Targeted search for potential readthrough peptides containing the other 19 amino acids in place of the stop codon was negative, supporting Ser insertion during UGA stop codon readthrough.
Ax Element Is the Necessary and Sufficient cis-Acting
Signal for Translational Readthrough of VEGFA mRNA To validate translation readthrough and investigate molecular mechanisms, we established a reporter assay in which the fulllength bovine VEGFA coding sequence (corresponding to VEGF-A 164 ) up to and including the 63 nt, Ax-specific sequence (termed Ax element) was cloned upstream of and in frame with firefly luciferase (FLuc). The downstream stop codon was excluded so that readthrough at the canonical stop codon generated a FLuc-containing chimeric protein. Transfected ECs exhibited substantially greater FLuc activity compared to vector alone or control reporters lacking the Ax element or replaced by a nonspecific sequence, consistent with translation readthrough ( Figure 3A ). To calculate readthrough efficiency, the upstream TGA stop codon was mutated to Ala-encoding GCA to maximize FLuc expression; stop codon readthrough efficiency was about 9%. Quantitative RT-PCR (qRT-PCR) analysis showed that all constructs were transcribed at similar levels, indicating that differential FLuc activity was due to differences in translation. Similar results were obtained by in vitro translation of the same reporters in rabbit reticulocyte lysates ( Figure S3A ). These results verify translational readthrough in VEGFA mRNA and show the essentiality of the Ax element, consistent with a PTR mechanism.
To investigate if the Ax element drives readthrough in the context of a heterologous transcript, a construct was engineered containing Myc terminated with a TGA stop codon, upstream and in frame to the Ax element and FLuc (Myc-Ax-FLuc). Transfection into ECs induced substantial FLuc activity compared to a control transcript without the Ax element or empty vector (Figure 3B, left) . The readthrough product was detected following immunoprecipitation using anti-Myc-tag antibody by immunoblot ( Figure 3B (legend continued on next page)
shown by in vitro translation in rabbit reticulocyte lysate (Figure S3C) . To determine the region of the Ax element necessary for function, deletions from both termini were generated (Figure 3C) . Deletion of 9, 21, or 42 nt from the 3 0 end or 6 nt from the 5 0 end substantially reduced FLuc activity, suggesting that both termini are required, and possibly the entire element, for efficient readthrough ( Figure 3D ). Next, we tested the ability of Ax element to execute readthrough across the other two stop codons, UAG and UAA. Surprisingly, similar Ax element-mediated VEGFA readthrough was observed across all three stop codons ( Figure 3E ), thereby rejecting single stop codon-dependent mechanisms, such as UGA-dependent selenocysteine insertion (Low and Berry, 1996) . Mutation of the first nucleotide after the canonical stop codon (denoted G1) did not affect the readthrough efficiency, ruling out context-dependent readthrough mechanisms observed in other systems (Poole et al., 1995; Tate et al., 1999) (Figure 3F ). Together, these experiments reveal the Ax element as the necessary and sufficient translational readthrough signal in VEGFA mRNA.
hnRNP A2/B1 Is a trans-Acting Enhancer of VEGFA Readthrough A near-consensus hnRNP A2/B1 recognition element (A2RE) was identified within the Ax element ( Figure 4A ). hnRNP A2/B1 is an RNA-binding protein involved in pre-mRNA processing and mRNA transport and binds the consensus sequence 5 0 -GCCAAGGAGCC-3 0 (He and Smith, 2009; Shan et al., 2003) . Surface plasmon resonance spectroscopy revealed a high-affinity interaction between hnRNP A2/B1 and a VEGFA RNA segment containing the A2RE, with a dissociation constant (K D ) of 19.2 ± 5.6 nM ( Figure 4B ). hnRNP A2/B1 is localized primarily in the nucleus; however, cytoplasmic localization was detected by immunofluorescence and by fractionation ( Figure 4C ). An RNA-binding protein immunoprecipitation (RIP) experiment confirmed the intracellular interaction between endogenous hnRNP A2/B1 and VEGFA mRNA ( Figure 4D ). To interrogate interaction specificity, ECs were transfected with a FLuc reporter bearing wild-type, mutant (AA-to-TT), or no Ax element. RIP followed by qRT-PCR analysis showed that hnRNP A2/B1 interacted with the wildtype Ax element, but not with the mutant element ( Figure 4E , left) (Munro et al., 1999) . Mutation of the A2RE also substantially reduced readthrough without altering mRNA expression (Figure 4E, right) . The low-level readthrough in the absence of hnRNP A2/B1 binding suggests that other factors might contribute, consistent with the requirement for the entire Ax element, not just the A2RE. Similarly, siRNA-mediated knockdown of hnRNP A2/B1 in ECs reduced readthrough of the VEGFA-Ax-FLuc reporter without inhibiting FLuc activity of a construct with Ala-encoding GCA in place of the canonical stop codon or with mutant Ax element ( Figure 4F ). Finally, hnRNP A2/B1 knockdown reduced endogenous expression of VEGF-Ax without affecting total VEGF-A protein or mRNA in ECs ( Figure 4G ). These observations show the important regulatory role of hnRNP A2/B1 as a trans-acting factor promoting PTR of VEGFA mRNA.
VEGF-Ax Exhibits Antiangiogenic Properties
Our EC migration and proliferation experiments in the presence of VEGF-A antibody indicated secretion of an antiangiogenic isoform of VEGF-A. Canonical VEGF-A isoforms were not detected in EC-conditioned medium immunodepleted with anti-VEGF-Ax antibody, confirming that VEGF-Ax is the predominant isoform secreted by ECs ( Figure S4A) . Also, the presence of RLTRKD (and absence of CDKPRR) at the C terminus suggests that VEGF-Ax is a novel antiangiogenic isoform. Anti-VEGF-Ax antibody increased EC migration and proliferation to an extent comparable to induction by recombinant VEGF-A, consistent with a paracrine, antiangiogenic activity of endogenous VEGF-Ax (Figures 5A and 5B; Figure S4B ). Purified, recombinant His-VEGFAx Ala markedly inhibited planar EC migration, tube formation in Matrigel, and proliferation ( Figures 5C-5E ). Similarly, siRNAmediated knockdown of hnRNP A2/B1, which reduces VEGFAx production, stimulated EC migration ( Figure S4C ). Together, these results indicate that VEGF-Ax is the predominant isoform of VEGF-A released by ECs, exerting a potent paracrine, antiangiogenic activity. To obtain insights into the mechanism of action of VEGF-Ax, we investigated its binding to VEGF receptors using solid-phase enzyme-linked receptor-binding assays. His-VEGFAx Ala and VEGF-A bound VEGFR2, with comparable affinities, but maximal binding of the former was marginally lower at high ligand concentration ( Figure 5F ). Importantly, His-VEGF-Ax Ala did not bind neuropilin 1, a critical VEGFR2 coreceptor (Figure 5G) . Likewise, His-VEGF-Ax Ala did not trigger canonical signaling pathways as shown by the failure to phosphorylate VEGFR2 Tyr residues Y1175 and Y951 ( Figure 5H ).
Pathophysiological Significance of VEGF-Ax
To determine the antiangiogenic function of VEGF-Ax in vivo, we used human xenograft tumors in nude mice. Administration of recombinant VEGF-Ax markedly reduced the progression of HCT116 (human colon carcinoma cell)-derived tumors (Figure 6A) . Furthermore, VEGF-Ax reduced tumor-associated angiogenesis as measured by the number of vessels directly feeding the tumors ( Figure 6B ). To further assess the physiological significance of VEGF-Ax, we determined its expression in vivo using a tissue microarray. VEGF-Ax was detected in tissue slices from human brain, colon, small intestine, spleen, and pancreas and from serum from healthy human subjects ( Figures S5A and S5B ). Staining of human colon tissue with (E) hnRNP A2/B1 binds the A2RE in VEGFA mRNA. VEGF-Ax-FLuc plasmid containing an Ax element with A2RE mutation (mut. Ax) was transfected into ECs. Anti-hnRNP A2/B1 immunoprecipitates were probed by qRT-PCR using FLuc-and GAPDH-specific TaqMan anti-VEGF-Ax antibody preadsorbed with AGLEEGASLRVSGTR peptide showed only background signal demonstrating antibody specificity in tissue immunofluorescence assays ( Figure S5C ). VEGF-Ax expression in tissues from pancreatic adenocarcinoma and glioblastoma was similar to that in corresponding healthy tissues (data not shown). Remarkably, VEGF-Ax expression was reduced to near-background level in cancerous tissues from grade 2 or 3 adenocarcinoma of colon, despite abundant VEGF-A expression ( Figure 6C ). These results not only show that VEGF-A translational readthrough occurs in vivo but also suggest a possible negative role of VEGF-Ax in tumor progression.
Genome-wide Analysis of Translational Readthrough
To identify additional translational readthrough candidates in mammals, we performed a genome-wide bioinformatic analysis. We interrogated a UTR database (Grillo et al., 2010) for mammalian transcripts with a stop codon in the 3 0 UTR in frame to the canonical stop codon and with amino acid conservation For all graphs, error bars represent SE; n = 3. See also Figure S4 . See also Figure S5 .
in the interstop codon region across five mammalian species ( Figure S6 ). This screen revealed VEGFA and five highprobability readthrough candidates (Figure 7A ). Candidates were tested by transfection of HEK293 cells with a plasmid containing about 700 nt of the 3 0 terminus of the human coding sequence of each candidate, followed by the interstop codon sequence and FLuc. MTCH2 and AGO1 showed robust readthrough activity ( Figure 7B ). Readthrough efficiency was determined by comparison to corresponding in-frame control constructs where UGA stop codon is replaced with Alaencoding GCA. Readthrough efficiency for VEGFA, MTCH2, and AGO1 was calculated to be 11%, 13%, and 24%, respectively.
DISCUSSION
Organisms have evolved a plethora of mechanisms at multiple levels to expand their proteomes relative to their surprisingly limited number of distinct genes. Among the most employed examples are alternative splicing and alternative polyadenylation at the posttranscriptional level, alternative initiation at the translational level, and protein cleavage and modification at the posttranslational level. There are multiple examples, but little mechanistic information about proteome expansion by translational readthrough that can generate proteins with extended C termini and potentially with alternate functions compared to the shorter, canonical form. Although some mechanistic insights have been provided by studies of translational readthrough in RNA viruses, little is known about mechanisms of translational readthrough in vertebrates and its role in proteome expansion. Here, we reveal a PTR event in VEGFA transcript that generates an antiangiogenic isoform, VEGF-Ax. Readthrough events have been described in vertebrate transcripts, for example, rabbit b-globin and rat myelin protein zero (Chittum et al., 1998; Yamaguchi et al., 2012) , and a recent ribosome profiling experiment provided evidence for translational readthrough of 42 mRNAs in human fibroblasts (Dunn et al., 2013) . However, the functional significance of the readthrough product has not been shown in any of these cases.
Basal readthrough levels ranging from 0.02% to 1.4% have been observed in yeast and mammalian cells (Dunn et al., 2013) . In viruses, where multiple readthrough events have been established, 6% efficiency in murine leukemia virus (MLV) and 2%-5% in Sindbis have been reported (Houck-Loomis et al., 2011; Li and Rice, 1989) . In these cases, the nucleotide sequence downstream of the canonical stop codon serves as a signal directing readthrough, establishing them as authentic programmed events unambiguously distinguishable from translation errors (Firth et al., 2011; Rajon and Masel, 2011) . For example, a 63 nt RNA element downstream of the stop codon induces translational readthrough in the MLV gag-pol gene (Houck-Loomis et al., 2011) . In our studies, the readthrough efficiency of VEGFA ranges from 7% to 25%. VEGFA mRNA readthrough is programmed by the Ax element, a 63-nt-long RNA sequence between the two stop codons that can drive readthrough in a heterologous system. We also identify hnRNP A2/ B1 as a trans-factor that binds the A2RE in the Ax element and positively regulates VEGFA readthrough. This finding is particularly noteworthy in that regulation of translational readthrough by a trans-factor has not been reported.
Although context-specific regulation of readthrough is suggested by a ribosome profiling study that showed differential readthrough of nine transcripts in two Drosophila cell types (Dunn et al., 2013) , molecular mechanisms underlying such regulation have not been elucidated in any system. As one possible mechanism, we speculate that the Ax element, in coordination with hnRNP A2/B1, interacts directly or indirectly (e.g., by inducing a pause) with the translating ribosomes and prevents eukaryotic releasing factor 1 (eRF1) binding to the stop codon. As a consequence, the UGA stop codon could instead be recognized by a suppressor tRNA or by near-cognate tRNAs resulting in readthrough. This mechanism is supported by several observations: (1) protein interactome studies suggest that hnRNP A2/ B1 interacts with several ribosomal proteins, including S7, S19, S28, L27a, and L39 (Havugimana et al., 2012; Kristensen et al., 2012) ; (2) ribosome occupancy is asymmetric at the stop codon, occupying 6 nt downstream of the stop codon (Ingolia et al., 2009) . The A2RE element starts at the 11 th nt following the stop codon, possibly facilitating an interaction between hnRNP A2/B1 and a ribosome paused at the stop codon, (3) aminoglycosides, which induce readthrough, also bind ribosomes (Howard et al., 2004; Kondo et al., 2005) , and (4) the observed readthrough of all three stop codons suggests that a single tRNA species may not be involved. A deep mechanistic understanding to the readthrough mechanism might require structural studies of the relationship of the Ax element and its binding partner with the paused ribosome. Serine was identified as the amino acid inserted in the place of the UGA codon during VEGFA mRNA readthrough. Interestingly, the tRNA that inserts selenocysteine (Sec) in place of UGA codons, namely tRNA [Ser] Sec , specifically recognizes UGA codons and is initially charged with Ser before it is phosphorylated and converted to Sec by Sec synthase (Turanov et al., 2011) . Moreover, Ser-tRNA [Ser] Sec can suppress termination at a UGA codon in rabbit b-globin mRNA in vitro (Chittum et al., 1998; Diamond et al., 1981 Arg are likely candidates, as they have been observed in other readthrough events involving the UGA stop codon, namely, in rabbit b-globin (Chittum et al., 1998) and gag-pol MLV (Feng et al., 1990) . However, these and other amino acids likely constitute a minor fraction, as they were not observed even after targeted mass spectrometry analysis. The observed readthrough across all stop codon types was unexpected, but nonsense suppression across all three stop codons has been reported in mammalian systems (Beier and Grimm, 2001; Hatfield et al., 1990) . Recognition of all three stop codons by eRF1 is also consistent with our finding of promiscuous readthrough (Kisselev et al., 2003) . Translational readthrough contributes significantly to the proteome expansion in yeast, Drosophila, and human fibroblasts (Dunn et al., 2013; Jungreis et al., 2011; von der Haar and Tuite, 2007) . Using a bioinformatic, genome-wide approach based on evolutionary conservation of the intrastop codon sequence, we have identified five additional putative readthrough targets, none of which have been previously described. Translational readthrough was experimentally validated in two mRNAs, AGO1 and MTCH2. MTCH2 induces apoptosis by recruiting tBID (truncated BH3-interacting domain death agonist) to mitochondria (Zaltsman et al., 2010) ; AGO1 (or EIF2C1) encodes Argonaute 1, an important participant in the microRNA and RNAi systems (Kim et al., 2006) . Although the other candidates (NR1D1, TOX1, and ADAMTS4) were inactive in our luciferasebased readthrough assay in HEK293 cells, they might be readthrough targets in other conditions or cells. The AGO1 and MTCH2 3 0 UTRs do not share sequence similarity with the Ax element, nor do they possess an A2RE, suggesting that their readthrough mechanisms are likely to be different from that of VEGFA mRNA.
The concept of antiangiogenic VEGF-A isoforms was introduced by the report of an alternative splicing event within the terminal exon of VEGFA to generate VEGFAb mRNA that replaces CDKPRR at the C terminus with SLTRKD, conferring antiangiogenic properties in vitro (Bates et al., 2002) . Several laboratories have shown that recombinant or overexpressed VEGF-Ab inhibits in vivo angiogenesis in murine tumor models, in mammary tissue of transgenic mice, and during neovascularization in mouse retina, rabbit cornea, and rat mesentery (Cé be Suarez et al., 2006 Cromer et al., 2010; Konopatskaya et al., 2006; Manetti et al., 2011; Qiu et al., 2008; Rennel et al., 2008 Rennel et al., , 2009 Woolard et al., 2004) . Lastly, immunological evidence for robust VEGF-Ab expression has been reported in multiple cells and tissues . Despite these promising observations, the in vivo expression of VEGF-Ab remains controversial, based in part on the observation that the RT-PCR methods used for detection and quantitation are prone to error (Bates et al., 2013; Harris et al., 2012) . Similarly, we were unable to detect VEGFAb mRNA isoforms in ECs despite robust expression of antiangiogenic activity. At present, detection by anti-VEGF-Ab antibody is considered the strongest support for expression of endogenous VEGFAb. However, this evidence is confounded by the presence of the same SLTRKD hexapeptide at the C termini in both VEGF-Ax and VEGF-Ab, and anti-VEGF-Ab antibodies raised against this region do not distinguish between the two isoforms.
In contrast, the antibody raised against the first 15 amino acids of the peptide extension of VEGF-Ax is highly specific for VEGF-Ax ( Figure S2B ). New tools and approaches are required to resolve the relative in vivo expression of the various pro-and antiangiogenic isoforms. Development of antibodies that recognize VEGF-Ab, but not VEGF-Ax, possibly by targeting the junction of the sequence encoded by exon 7 and SLTRKD, would be extremely helpful. Also, RNA sequencing analysis could not only provide strong support for expression of VEGFAb isoforms but also offer insight into the relative amounts of differentially spliced VEGFA and VEGFAb isoforms in a given tissue or cell type.
VEGF-Ax exhibits potent antiangiogenic activity as evidenced by inhibition of EC migration, proliferation, and tube formation in vitro and tumor growth and associated angiogenesis in vivo. A report of enhanced EC sprouting in aortic rings from mice heterozygous for EC-specific VEGFA gene deletion (da Silva et al., 2010) is consistent with our finding of predominant antiangiogenic VEGF-Ax in EC-conditioned medium. The discovery of antiangiogenic VEGF-A isoforms compels a need for cognizance and caution in applying VEGF-A-targeted therapies for treatment of VEGF-A-dependent malignancies, as coincident diminution of VEGF-Ax may exacerbate angiogenesis and tumorigenesis Varey et al., 2008) . Moreover, usefulness of VEGF-A as a biomarker might also need to be reconsidered in the view of potential presence of both proand antiangiogenic isoforms. We speculate that expression of VEGF-Ax is an innate mechanism that evolved to limit EC movement and angiogenesis during tissue homeostasis and to reduce pathological angiogenesis. However, in some conditions exemplified by colon adenocarcinoma in our study, a loss of expression of VEGF-Ax might induce angiogenesis and exacerbate pathogenesis. Thus, abnormally low levels of VEGF-Ax in plasma or tissues can serve as a biomarker for prognosis or effective susceptibility to current anti-VEGF treatment. Moreover, because of its robust antiangiogenic activity, VEGF-Ax provides a potential therapeutic agent against diseases characterized by excessive angiogenesis.
EXPERIMENTAL PROCEDURES
Cell Culture Bovine aortic ECs were cultured in Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 medium containing 5% fetal bovine serum (FBS) and used in all experiments unless specified otherwise. Human umbilical vein ECs (HUVECs) were cultured in EC growth medium with SingleQuots supplements (Lonza). HEK293 cells were cultured in DMEM containing 10% FBS. Cells were maintained at 37 C in a humidified atmosphere with 5% CO 2 .
Luciferase-Based Translational Readthrough Assay Plasmids containing chimera of FLuc downstream of test sequences (VEGFA, Myc, TOX, ADAMTS4, AGO1, NR1D1, or MTCH2) were transfected (500 ng/well) into bovine ECs or HEK293 cells in 24-well plates using Lipofectamine 2000. Plasmid expressing Renilla luciferase (RLuc) (50 ng/well) was cotransfected as efficiency control. After 48 hr, cells were lysed and FLuc and RLuc activity were measured using Dual-Luciferase Reporter Assay System (Promega) in a Victor3 1420 Multilabel Plate Counter (Perkin-Elmer). The same constructs were subjected to in vitro coupled transcription-translation (500 ng/reaction) using TNT T7 coupled rabbit reticulocyte lysates (Promega) and FLuc activity measured by Luciferase Assay System (Promega).
Animal Studies
Nu/Nu athymic nude male mice were inoculated subcutaneously on both flanks with HCT116 human colon carcinoma cells. Mice were injected subcutaneously with His-VEGF-Ax (10 mg/mouse) obtained from HEK293 cells stably expressing bovine VEGF-Ax with Ser in place of the canonical stop codon. HiTrap Heparin HP Columns (GE Healthcare) were used for purification. Control mice were injected with buffer containing 25 mM Tris and 150 mM NaCl (pH 8). Injections were given every third day starting from the fourth day after tumor inoculation. Tumor progression was monitored by caliper determination of volume [(shortest diameter) 2 3 (longest diameter) 3 0.525]. For determination of tumor angiogenesis, treatment was started on the second day after tumor inoculation, and blood vessels feeding directly into day 6 tumors were counted under a dissecting microscope at 12.53 magnification. Images were captured using PSMT5 operating microscope (World Precision) with 12.5 3 objective lens; every visible vessel touching the circumference of the tumor nodule was scored as a single vessel by an observer blinded to the treatment. 
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